The core challenge in treating PDAC has long been its molecular complexity and the resilience of its tumors, which evolve rapidly to evade therapeutic interventions. Traditional chemotherapies have yielded limited success over decades, and recent advancements targeting the KRAS oncogene, mutated in approximately 90% of pancreatic cancers, have shown promising yet transient effects. KRAS inhibitors initially arrest tumor growth but soon face the obstacle of adaptive resistance, causing therapeutic efficacy to wane within months. The CNIO team, led by Mariano Barbacid, has tackled this issue with a strategic innovation: simultaneously targeting three critical nodes within the KRAS signaling cascade, thereby creating a triad of inhibition that hampers the tumor’s ability to compensate or bypass the blockade.

This triple therapy approach is conceptually akin to reinforcing a fragile beam at three points instead of one, dramatically reducing the likelihood of structural failure. By genetically ablating three molecular targets downstream of KRAS in murine models, the researchers observed near-complete regression of pancreatic tumors, with remarkably enduring results and an absence of relapse. This contrasts starkly with prior single-agent therapies, where the tumor swiftly adapts through alternate pathways or mutations. Importantly, these genetic insights have been translated into pharmacological intervention, coupling an experimental KRAS inhibitor, daraxonrasib (also known as RMC-6236), with afatinib, an EGFR inhibitor approved for lung adenocarcinoma, alongside a STAT3 protein degrader, SD36. This triple regimen demonstrated sustained tumor regression in diverse mouse models, marking a significant stride toward clinical applicability.

The sophisticated design of this therapy reflects a deep understanding of PDAC’s molecular circuitry. KRAS mutations drive tumorigenesis through several downstream effectors, including the RAF-MEK-ERK pathway, the EGFR axis, and STAT3, a transcription factor promoting oncogenic inflammation and survival. Individually inhibiting these components has proved insufficient due to compensatory signaling, but their concurrent blockade yields a synergistic shutdown of tumor sustenance. The researchers meticulously confirmed that this multi-pronged inhibition not only induces tumor cell death but also impedes resistance mechanisms, a notorious barrier in PDAC therapies. Crucially, the treatment was well tolerated in mice, alleviating concerns about potential systemic toxicity from targeting multiple pathways.

While the implications of these findings are profound, the path toward human clinical trials remains cautious. Mariano Barbacid underscores that despite the unprecedented preclinical success, further optimization and safety evaluations are imperative before embarking on trials involving patients. The complexity of translating combination therapies requires meticulous pharmacokinetic and pharmacodynamic assessments, dosage calibrations, and careful monitoring to circumvent adverse effects. Nonetheless, these results open an optimistic avenue for devising next-generation treatments that could significantly extend survival for PDAC patients, who currently face dismal prognoses with few therapeutic options.

The scientific community has taken note of this breakthrough, which appears in the prestigious Proceedings of the National Academy of Sciences (PNAS). The article, co-led by Carmen Guerra and with first authors Vasiliki Liaki and Sara Barrambana, meticulously details the experimental design, molecular rationale, and therapeutic outcomes that underpin this innovative strategy. The study represents a culmination of decades of foundational work elucidating KRAS-driven oncogenesis and overcoming the challenge of tumor resistance, demonstrating how targeted molecular therapies can be precisely tailored to the biology of aggressive cancers.

Pancreatic cancer remains a formidable opponent, with over 10,300 new cases diagnosed annually in Spain alone. The aggressive nature of the disease, combined with silent symptomatology, often results in late detection after metastasis, complicating treatment efforts. The CNIO team’s pioneering work addresses these hurdles by developing a mechanism-based therapy grounded in molecular oncology principles, leveraging recent advances in drug development, and repurposing agents like afatinib in novel contexts. This integrative approach exemplifies modern cancer therapeutics, where combination regimens are designed based on tumor biology rather than empirical drug combinations.

The research also highlights the importance of collaborative funding and resource allocation to tackle challenging cancers. Supported by Fundación CRIS Contra el Cáncer, the European Research Council, and multiple national and international agencies, this project underscores how strategic investment in cutting-edge oncology research can yield transformative clinical prospects. The study’s authors anticipate that continuous refinement of this triple therapy, alongside biomarker development to monitor efficacy and resistance, will pave the way for clinical translation within a foreseeable timeframe.

Notably, the study includes a conflict-of-interest statement disclosing patent applications related to the triple therapy and involvement of some researchers in clinical trials with daraxonrasib, ensuring transparency in the scientific discourse. These patent filings indicate a forward-looking vision to commercialize and disseminate the therapy pending successful clinical validation. Concurrent trials in pancreatic cancer with KRAS inhibitors will provide invaluable comparative data, informing future therapeutic strategies and potential combination regimens.

In summary, this landmark study from CNIO offers a beacon of hope in the battle against pancreatic cancer. By ingeniously circumventing the adaptive resistance mechanisms of PDAC tumors through a targeted triple therapy, the researchers have demonstrated a blueprint for durable tumor control. This work not only enhances our molecular understanding of KRAS-driven cancers but also sets a compelling precedent for the development of combination therapies in oncology. The transition from bench to bedside, while necessitating rigorous validation, may ultimately deliver improved outcomes for patients afflicted by this devastating disease.

Subject of Research: Animals

Article Title: A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance

News Publication Date: 2-Dec-2025

Web References:
https://www.pnas.org/doi/10.1073/pnas.2523039122

References:
Barbacid, M., Guerra, C., Liaki, V., Barrambana, S., et al. (2025). A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.2523039122.

Image Credits: CNIO Molecular Oncology Group, Credit: MadMoviex. CNIO

Keywords: Pancreatic cancer, Tumor regression, Oncology, Drug resistance, Drug targets

Pancreatic cancer is notorious for its high mortality rate and is often diagnosed at an advanced stage due to its subtle symptoms and aggressive nature. The clinical scenario often involves the presence of liver metastases, which significantly limits treatment options. However, the concept of conversion therapy—wherein chemotherapy is used to shrink tumors, making them amenable to surgical resection—has begun to gain traction in recent years. The case presented is pivotal as it suggests that patients previously deemed unsuitable for surgery might benefit from this strategy.

Specifically, the research discusses a patient with pancreatic cancer who also had multiple liver lesions. Through a tailored regimen of systemic therapy, the patient’s response to treatment was monitored closely. Evaluations revealed a significant reduction in tumor burden, allowing the patient to transition from a palliative setting to one where surgical intervention could be contemplated. This transformation is particularly noteworthy, as traditional approaches often do not accommodate such aggressive metastatic presentations.

R0 resection refers to the surgical removal of all visible tumor, ensuring no residual cancer cells are left behind. Achieving R0 resection in patients with metastatic disease is a rare but critical outcome that can enhance survival rates. The authors detail the meticulous surgical procedure involved in the R0 resection of the pancreas, highlighting how thorough staging and imaging studies guided surgical planning. Notably, this kind of surgical precision is essential in maximizing patient outcomes.

The implications of successful conversion therapy preceding R0 resection cannot be overstated. It challenges the prevailing notion that pancreatic cancer with liver metastases is merely a terminal diagnosis. Instead, this case suggests that with a multifaceted treatment approach, aggressive management paired with surgical resections can lead to long-term survivorship. The study also emphasizes the importance of multidisciplinary teams in achieving this outcome, as each specialist contributes unique insights to optimize patient care.

Moreover, the researchers address the complexities involved in selecting candidates for this type of aggressive treatment regimen. An extensive understanding of tumor biology, patient health status, and careful monitoring of treatment response are all quintessential aspects that influence decision-making. The physicians involved in this case underwent a series of assessments to determine the optimal timing for surgery, underscoring the need for precision in clinical oncology.

Further along in their analysis, the authors highlight the significance of biomarkers in gauging treatment responses. Emerging genomic and molecular characteristics of tumors could play a role in predicting which patients are likely to benefit from conversion therapy. As research advances, the integration of precision medicine may provide valuable tools in personalizing treatment strategies.

The psychological implications for patients undergoing such intense treatment protocols are also worth considering. The emotional and mental resilience required to navigate through uncertainty and rigorous therapy regimens cannot be underestimated. Survivorship offers hope but can also bring psychological sacrifices, which necessitate comprehensive support systems tailored to patients’ needs throughout their journeys.

In an ever-evolving field like oncology, the importance of continuous clinical trials cannot be understated. This case report emphasizes the need for larger cohort studies to validate the findings and expand upon them. Establishing statistically significant outcomes with diverse populations will enlist more patients into clinical protocols that could prolong life and improve quality.

The authors conclude with a note about the future direction of pancreatic cancer treatment, suggesting that incorporating novel agents and therapeutic strategies could further enhance the effectiveness of conversion therapy. The growing body of research surrounding immunotherapies and targeted therapies presents exciting opportunities that could redefine treatment possibilities.

Innovative surgical techniques alongside medical therapy create new avenues for treatment in patients with historically grim prognoses. This case serves not only as a beacon of hope for patients but also as an impetus for ongoing research and collaboration among experts in the field to dissect complex cases of metastatic disease.

In summary, the case presented by Dong et al. exemplifies how conversion therapy followed by successful R0 resection can change the narrative around pancreatic cancer with liver metastases. It challenges pre-existing benchmarks, provides new insights into patient management, and inspires further research that may ultimately pave the way for improved outcomes in a historically difficult-to-treat cancer.

Subject of Research: Conversion therapy and surgical resection in pancreatic cancer with liver metastases

Article Title: Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report

Article References: Dong, S., Gao, Y., Wang, Z. et al. Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report. J Cancer Res Clin Oncol 151, 200 (2025). https://doi.org/10.1007/s00432-025-06180-3

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06180-3

Keywords: pancreatic cancer, conversion therapy, R0 resection, liver metastases, oncology research, surgical oncology

PHOENIX, Ariz. — April 30, 2025 — HonorHealth Research Institute’s new downtown Phoenix laboratory has produced its first study, centered on a promising new treatment for pancreatic cancer, one of the most aggressive and difficult to treat of all malignancies.

Study results were presented April 29 in Chicago at the annual meeting of the 58,000-member American Association for Cancer Research (AACR), the world’s largest professional organization of cancer investigators, caregivers and patient advocates.

Study findings indicate that a newly discovered drug, RMC-6236, also known as Daraxonrasib, is a powerful inhibitor of RAS (including KRAS, NRAS and HRAS). These are commonly mutated cancer-causing genes that drive the formation of many types of tumors, including pancreatic cancer.  This study evaluated the effectiveness of RMC-6236 in patient-derived pancreatic tumors harboring KRAS mutations.

New: Center for Translational Science

According to this initial study to emerge from the Research Institute’s new Center for Translational Science laboratory, RMC-6236, when combined with other proven pancreatic cancer drugs, is a promising new agent against RAS, particularly KRASG12X. Existing KRASG12C inhibitors are unable to target other mutations and often have the unintended result of making  patient tumors drug resistant.

“The fibrotic tumor microenvironment in pancreatic cancer exacerbates therapy resistance, and combining RMC-6236 with other therapies could overcome both intrinsic and acquired resistances,” according to Taylor Bargenquast, a clinical research technician and lead author of the study abstract, which she presented at AACR.

“These results demonstrate the efficacy of RMC-6236 when combined with other therapeutic agents in a pancreatic cancer model — a three dimensional model of pancreatic cancer cells derived from patient biopsies,” said Sunil Sharma, M.D., director of the Center for Translational Science and the senior author of the study abstract.

“The combination of RMC-6236 with standard chemotherapy and targeted therapies enhances its antitumor activity, suggesting a promising strategy for improving therapeutic outcomes in pancreatic cancer,” said Erkut Borazanci, M.D., another of the study’s authors, and medical director of the Institute’s Oncology Research Division.

52,000 Americans expected to die

Pancreatic cancer is the third-leading cause of cancer-related death in the U.S., after lung and colorectal cancers, and is expected to contribute this year to the deaths of nearly 52,000 Americans.

Contributing to this study — Evaluating the efficacy of RAS(ON) inhibitor RMC-6236 combined with chemotherapy and other targeted therapies in 3D models involving patients with KRAS-mutated pancreatic cancer — was the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope.

The study suggests that human clinical trials are warranted to further evaluate the safety and effectiveness of RMC-6236.

For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or emailclinicaltrials@Honorhealth.com.

# # #

About the HonorHealth Research Institute
HonorHealth Research Institute is an international destination that is at the forefront of providing patients with a better quality of life through its clinical trials and innovative treatment options. Headquartered in Scottsdale, Arizona, the institute’s team of physicians and researchers collaborate with experts from across the nation to offer life-changing therapies, drugs and devices. At HonorHealth Research Institute, patients have access to tomorrow’s health innovations, today. Learn more at: HonorHealth.com/research.
 

Meeting

AACR Annual Meeting 2025

The efficacy of immune therapies has been a beacon of hope for many cancer patients, particularly with the emergence of checkpoint inhibitors that empower the immune system to identify and destroy cancer cells. Nonetheless, the limitations of these therapies are starkly evident in solid tumors. Tumor microenvironments are often characterized by nutrient deprivation, elevated acidity, and hypoxic (low oxygen) conditions, all of which lead to T cell exhaustion and hinder their anti-tumor functions. In high-mortality cancers, such as pancreatic cancer, this hostile environment becomes even more damaging, rendering conventional immunotherapies less effective.

Dr. Samantha Pretto, the lead author of the study, emphasizes a pivotal question: “What if we can reprogram T cells so that they can use a different nutrient?” Her sentiment reflects a paradigm shift in thinking about T cells not merely as reactive agents of the immune system, but as adaptable entities capable of metabolic reengineering. The research team diligently focused on the biochemical pathways that regulate T cell activity, with the objective of identifying strategies to support T cell survival and efficacy in the challenging contexts of solid tumors.

Central to their findings is the enzyme Elovl1, which they identified as a critical target for metabolic intervention in T cells. By inhibiting Elovl1, the researchers enabled T cells to switch from glucose metabolism, which is often compromised within tumors, to fatty acid oxidation. This metabolic maneuver not only enhances the energy efficiency of T cells but also fortifies their proliferation and anti-tumor capabilities. The ability of T cells to persist longer within tumors signifies a substantial leap toward improving patient outcomes—a concept previously deemed elusive.

The implications of this metabolic reprogramming extend beyond mere survival in adverse conditions; they enhance the arsenal of T cells in mounting a formidable defense against cancer cells. Professor Max Mazzone, a co-author of the study, articulates the significance of the research: “This study offers a genetic analysis of multiple metabolic pathways at the primary tumor and metastatic sites, disclosing how altering these pathways can empower T cell phenotypes.” By documenting the metabolic transformations and their impact on T cell behavior, the research paves the way for developing more effective immunotherapeutic strategies.

Encouragingly, the researchers demonstrated that the combination of Elovl1 blockade with current immune checkpoint therapies resulted in striking improvements in T cell responses within preclinical models of melanoma and pancreatic cancer. This synergistic effect showcases a novel strategy to outsmart the inherent defenses of tumors, amplifying the potential for successful treatment outcomes. Such findings are pivotal, as they not only boost the efficacy of therapies but also provide hope for patients who have exhausted available treatment options.

The study instigates critical discussions about the future of cancer treatment, particularly regarding metabolic manipulation of immune cells. Traditional approaches have predominantly emphasized restoring immune recognition through checkpoint modulation. However, this new insight brings to light the necessity to consider the metabolic state of immune cells as a fundamental component in enhancing their functionality. Understanding these metabolic dynamics could lead to the development of treatments that are not only more effective but also uniquely suited to individual patient profiles.

As research continues to evolve, the potential for transforming cancer therapy through metabolic reprogramming appears boundless. By tapping into the intricacies of cellular metabolism, scientists can forge pathways that not only improve T cell endurance and lethality against tumors but also complement existing therapies, optimally matching therapeutic strategies to the metabolic profiles of different tumor types. The potential applications of this research may extend well beyond solid tumors, offering insights into a myriad of cancers characterized by similar immune evasion strategies.

In summary, the work of the VIB-KU Leuven team represents a vital intersection of immunology and metabolism, a fusion that could unlock new frontiers in cancer therapy. As we look to the future, the prospect of successfully harnessing the power of our immune system through such innovative approaches is not only promising—it is essential. This study serves as a testament to the relentless pursuit of scientific discovery in the face of one of humanity’s most formidable challenges.

In conclusion, the findings from this ambitious research initiative underscore the importance of metabolic flexibility in enhancing the capabilities of T cells. By engineering T cells to adapt to their environment through metabolic reprogramming, we envisage a future in which cancer therapies are not just about targeting tumors but also about empowering the immune system to function optimally. The journey toward unlocking the full potential of immunotherapy is, indeed, one marked by innovation, with researchers continually striving to pave the way for breakthroughs that could transform lives in the fight against cancer.

Subject of Research: Animals
Article Title: A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8+ T cell fitness in solid tumours
News Publication Date: 10-Mar-2025
Web References: http://dx.doi.org/10.1038/s42255-025-01233-w
References: Not applicable
Image Credits: Not applicable

Keywords: Solid tumors, T lymphocytes, Cell therapies, Primary tumors, Immune system